Nektar Therapeutics Profit Margin

The latest profit margin for NKTR is -284.18% as of March 2026. That compares with -152.49% in the prior-year period — down 86.4% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Nektar Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NKTR's profit margin moved from -152.49% to -284.18% — a 86.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nektar Therapeutics's valuation or profitability profile.

Against Healthcare companies, NKTR currently prints -284.18% for profit margin, while the sector average sits near 14.34%. That is roughly 2081.1% below the sector mean. Large gaps often invite a closer look at Nektar Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Nektar Therapeutics converts resources into returns. At -284.18%, NKTR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -152.49% in the prior-year period — down 86.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NKTR's profit margin (-284.18%), review year-over-year change from -152.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.